The outcomes of glucose abnormalities in pre‐diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy

Pre‐diabetes is a risk factor for type 2 diabetes mellitus (DM) development. This study aimed to elucidate the impact of treatment response on sequential changes in glucose abnormalities in pre‐diabetic chronic hepatitis C (CHC) patients.

[1]  Ming‐Lung Yu,et al.  Role of interleukin‐28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients , 2011, Hepatology.

[2]  V. Basevi.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[3]  Ming‐Lung Yu,et al.  Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community‐based Study , 2010, The Kaohsiung journal of medical sciences.

[4]  Ming‐Lung Yu,et al.  Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients , 2010, Hepatology international.

[5]  William M. Lee,et al.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. , 2010, Gastroenterology.

[6]  D. Williamson,et al.  A1C Level and Future Risk of Diabetes: A Systematic Review , 2010, Diabetes Care.

[7]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[8]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[9]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[10]  Ming‐Lung Yu,et al.  Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. , 2009, Journal of hepatology.

[11]  Ming‐Lung Yu,et al.  Treatment of chronic hepatitis C in Asia: When East meets West , 2009, Journal of gastroenterology and hepatology.

[12]  Hiroshi Kambe,et al.  Combined Measurement of Fasting Plasma Glucose and A1C Is Effective for the Prediction of Type 2 Diabetes , 2009, Diabetes Care.

[13]  Shang-Jyh Hwang,et al.  Reappraisal of the Characteristics of Glucose Abnormalities in Patients With Chronic Hepatitis C Infection , 2008, The American Journal of Gastroenterology.

[14]  R. Andrade,et al.  Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. , 2008, Journal of hepatology.

[15]  J. Hoekstra,et al.  High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon α for chronic hepatitis C virus infection , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[16]  Ding‐Shinn Chen,et al.  High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[17]  M. Hsieh,et al.  Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C , 2007, Journal of Clinical Pathology.

[18]  Shang-Jyh Hwang,et al.  Hepatitis C Viremia Increases the Association With Type 2 Diabetes Mellitus in a Hepatitis B and C Endemic Area: An Epidemiological Link With Virological Implication , 2007, The American Journal of Gastroenterology.

[19]  T. Kawaguchi,et al.  Clearance of HCV Improves Insulin Resistance, Beta-Cell Function, and Hepatic Expression of Insulin Receptor Substrate 1 and 2 , 2007, The American Journal of Gastroenterology.

[20]  D. Isenberg,et al.  Syndromes and complications of interferon therapy , 2007, Current opinion in rheumatology.

[21]  C. Dai,et al.  Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? , 2006, Journal of internal medicine.

[22]  J. Petit,et al.  Proinflammatory Cytokines, Insulin Resistance, and Insulin Secretion in Chronic Hepatitis C Patients: A Case-Control Study , 2006, Diabetes Care.

[23]  M. Hsieh,et al.  The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon‐alpha and ribavirin combination therapy , 2006, Journal of viral hepatitis.

[24]  Ming‐Lung Yu,et al.  Treatment of Chronic Hepatitis C in Southern Taiwan , 2005, Intervirology.

[25]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[26]  R. Andrade,et al.  Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. , 2005, Gastroenterology.

[27]  A. Basu,et al.  Chronic Hepatitis C and Type II Diabetes Mellitus: A Prospective Cross-Sectional Study , 2005, The American Journal of Gastroenterology.

[28]  T. Kawaguchi,et al.  Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. , 2004, The American journal of pathology.

[29]  Yuk-Lin Renita Wong.  When East Meets West , 2004 .

[30]  K. Koike,et al.  Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. , 2004, Gastroenterology.

[31]  Valeer J Desmet,et al.  Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 1981;1:431-435]. , 2003, Journal of hepatology.

[32]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[33]  J. Cadranel,et al.  Diabetes mellitus during interferon therapy for chronic viral hepatitis. , 2002, Digestive diseases and sciences.

[34]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.

[35]  C. Kahn,et al.  Insulin signalling and the regulation of glucose and lipid metabolism , 2001, Nature.

[36]  U. Phan,et al.  Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. , 1999, Journal of hepatology.

[37]  M. Matsuhisa,et al.  Interferon induces insulin resistance in patients with chronic active hepatitis C. , 1998, Journal of hepatology.

[38]  S. Hadziyannis.  The spectrum of extrahepatic manifestations in hepatitis C virus infection , 1997, Journal of viral hepatitis.

[39]  N. Boyer,et al.  Non-Insulin-Dependent Diabetes Mellitus Developing during Interferon- Therapy for Chronic Hepatitis C , 1996, Annals of Internal Medicine.

[40]  R. Frydman,et al.  Trancervical Sampling: A Preliminary Prospective Study , 1994, Annals of the New York Academy of Sciences.

[41]  P. Bedossa,et al.  Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C , 1994 .

[42]  M. Sakamoto,et al.  Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. , 1993, The Journal of general virology.

[43]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[44]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[45]  S. Juo,et al.  Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. , 2012, Journal of hepatology.

[46]  N. Boyer,et al.  Non-insulin-dependent diabetes mellitus developing during interferon-alpha therapy for chronic hepatitis C. , 1996, Annals of internal medicine.

[47]  J Trevelyan,et al.  East meets West. , 1991, Nursing times.